Cargando…
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
BACKGROUND: The logic behind the outcome of endocrine therapy in breast cancer has long remained poorly understood. The prognostic role of DNA damage and repair biomarkers (DDR) was explored in postmenopausal, hormone-receptor-positive breast cancer patients treated with neoadjuvant hormone therapy...
Autores principales: | Di Benedetto, Anna, Ercolani, Cristiana, Pizzuti, Laura, Angelucci, Domenico, Sergi, Domenico, Marinelli, Camilla, Iezzi, Laura, Sperati, Francesca, Terrenato, Irene, Mazzotta, Marco, Mariani, Luciano, Vizza, Enrico, Paoletti, Giancarlo, Tomao, Silverio, Maugeri-Saccà, Marcello, Barba, Maddalena, Tinari, Nicola, Natoli, Clara, Ciliberto, Gennaro, Grassadonia, Antonino, Vici, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700857/ https://www.ncbi.nlm.nih.gov/pubmed/31452691 http://dx.doi.org/10.1177/1758835919853192 |
Ejemplares similares
-
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020) -
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
por: Barba, Maddalena, et al.
Publicado: (2017) -
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes
por: Di Benedetto, Anna, et al.
Publicado: (2016) -
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
por: Grassadonia, Antonino, et al.
Publicado: (2021) -
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)